Arabic Arabic English English French French German German
dark

Public Meeting on Patient Focused Drug Development for Alpha 1 Antitrypsin Part 2

On September 29, 2015, FDA hosted a public meeting on Patient-Focused Drug Development for Alpha-1 Antitrypsin. FDA was interested in obtaining patient perspectives on the impact of Alpha-1 Antitrypsin on daily life and patient views on treatment approaches. For more information, visit https://go.usa.gov/xHpRE.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

The State of Gene Therapy

Next Post

Media Advisory — MIT researchers: AI policy needed to manage impacts, build more equitable systems

Related Posts
Total
0
Share